HK1098460A1 - Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders - Google Patents
Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disordersInfo
- Publication number
- HK1098460A1 HK1098460A1 HK07104630A HK07104630A HK1098460A1 HK 1098460 A1 HK1098460 A1 HK 1098460A1 HK 07104630 A HK07104630 A HK 07104630A HK 07104630 A HK07104630 A HK 07104630A HK 1098460 A1 HK1098460 A1 HK 1098460A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- sup
- compounds
- fused
- gastrointestinal disorders
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54528804P | 2004-02-18 | 2004-02-18 | |
US54558004P | 2004-02-19 | 2004-02-19 | |
PCT/US2005/005218 WO2005080397A2 (en) | 2004-02-18 | 2005-02-17 | Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1098460A1 true HK1098460A1 (en) | 2007-07-20 |
Family
ID=34886171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07104630A HK1098460A1 (en) | 2004-02-18 | 2007-04-30 | Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders |
Country Status (19)
Country | Link |
---|---|
US (1) | US20070185095A1 (sl) |
EP (1) | EP1716152B1 (sl) |
JP (1) | JP2007523183A (sl) |
KR (1) | KR20070026380A (sl) |
AT (1) | ATE402935T1 (sl) |
BR (1) | BRPI0507495A (sl) |
CA (1) | CA2556320A1 (sl) |
DE (1) | DE602005008558D1 (sl) |
DK (1) | DK1716152T3 (sl) |
ES (1) | ES2309718T3 (sl) |
HK (1) | HK1098460A1 (sl) |
HR (1) | HRP20080480T3 (sl) |
IL (1) | IL177291A0 (sl) |
MY (1) | MY152888A (sl) |
PL (1) | PL1716152T3 (sl) |
PT (1) | PT1716152E (sl) |
RU (1) | RU2006129324A (sl) |
SI (1) | SI1716152T1 (sl) |
WO (1) | WO2005080397A2 (sl) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4637578B2 (ja) | 2002-08-09 | 2011-02-23 | アストラゼネカ アクチボラグ | 代謝調節型グルタミン酸受容体−5の調節因子としての1,2,4−オキサジアゾール類 |
US7807706B2 (en) | 2005-08-12 | 2010-10-05 | Astrazeneca Ab | Metabotropic glutamate-receptor-potentiating isoindolones |
UY29796A1 (es) | 2005-09-29 | 2007-04-30 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor |
TW200808800A (en) * | 2006-05-05 | 2008-02-16 | Astrazeneca Ab | MGluR5 modulators V |
TW200811157A (en) | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
TW200811179A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators VI |
TW200835502A (en) * | 2006-12-26 | 2008-09-01 | Daiichi Sankyo Co Ltd | Thiazepine derivatives |
TWI417100B (zh) * | 2007-06-07 | 2013-12-01 | Astrazeneca Ab | 二唑衍生物及其作為代謝型麩胺酸受體增效劑-842之用途 |
TW200911255A (en) | 2007-06-07 | 2009-03-16 | Astrazeneca Ab | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841 |
WO2009054793A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Thiophene 1,2,4-triazole derivatives as modulators of mglur5 |
WO2009054789A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,3-triazole pyrrolidine derivatives as modulators of mglur5 |
WO2009054791A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5 |
WO2009054792A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Aminopyridine derivatives as modulators of mglur5 |
WO2009054786A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5 |
SA109300358B1 (ar) | 2008-06-06 | 2012-11-03 | استرازينيكا ايه بي | مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
JP5575913B2 (ja) | 2009-11-30 | 2014-08-20 | ノバルティス アーゲー | アルドステロン合成酵素阻害剤としてのイミダゾール誘導体 |
JP5775094B2 (ja) * | 2009-12-29 | 2015-09-09 | イーライ リリー アンド カンパニー | 統合失調症の処置に有用な選択的mGlu5受容体増強因子としてのテトラヒドロトリアゾロピリジン化合物 |
US20120295942A1 (en) | 2010-02-01 | 2012-11-22 | Nicholas James Devereux | Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
ES2627688T3 (es) | 2010-04-02 | 2017-07-31 | Ogeda Sa | Novedosos compuestos antagonistas selectivos del receptor de NK-3, composición farmacéutica y métodos para uso en trastornos mediados por los receptores de NK-3 |
US10065960B2 (en) | 2010-04-02 | 2018-09-04 | Ogeda Sa | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
CA2795218A1 (en) * | 2010-04-30 | 2011-11-03 | Helen Blade | Polymorphs of a metabotropic glutamate receptor positive allosteric modulator |
CN103906750B9 (zh) | 2011-10-03 | 2016-10-12 | 欧洲筛选有限公司 | 作为选择性NK-3受体拮抗剂的新型手性N-酰基-5,6,7,(8-取代的)-四氢-[1,2,4]三唑并[4,3-a]吡嗪、药物组合物、用于NK-3受体介导的疾病中的方法及其手性合成 |
WO2014154896A1 (en) | 2013-03-29 | 2014-10-02 | Euroscreen Sa | NOVEL N-ACYL-(3-SUBSTITUTED)-5,6,7,8-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS |
US9840508B2 (en) | 2013-03-29 | 2017-12-12 | Oged Sa | N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders |
SG11201508005XA (en) | 2013-03-29 | 2015-10-29 | Euroscreen Sa | NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS |
US10183948B2 (en) | 2013-03-29 | 2019-01-22 | Ogeda Sa | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
GB201312800D0 (en) | 2013-07-17 | 2013-08-28 | Heptares Therapeutics Ltd | mGlu5 modulators |
TR201902080T4 (tr) | 2014-09-25 | 2019-03-21 | Ogeda Sa | N-asil-(3-sübstitüe)-(8-sübstitüe)-5,6-dihidro-[1,2,4]triazolo[4,3-a]pirazinlerinin yeni kiral sentezleri. |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1210344T3 (da) * | 1999-08-19 | 2006-03-06 | Nps Pharma Inc | Heteropolycykliske forbindelser og anvendelser deraf som metabotrope glutamatreceptorantagonister |
JP2006502134A (ja) * | 2002-08-09 | 2006-01-19 | アストラゼネカ アクチボラグ | 代謝調節型グルタミン酸受容体において活性を有する化合物 |
-
2005
- 2005-02-17 AT AT05713794T patent/ATE402935T1/de not_active IP Right Cessation
- 2005-02-17 PL PL05713794T patent/PL1716152T3/pl unknown
- 2005-02-17 EP EP05713794A patent/EP1716152B1/en active Active
- 2005-02-17 ES ES05713794T patent/ES2309718T3/es active Active
- 2005-02-17 US US10/588,699 patent/US20070185095A1/en not_active Abandoned
- 2005-02-17 DE DE602005008558T patent/DE602005008558D1/de not_active Expired - Fee Related
- 2005-02-17 JP JP2006554237A patent/JP2007523183A/ja not_active Withdrawn
- 2005-02-17 DK DK05713794T patent/DK1716152T3/da active
- 2005-02-17 CA CA002556320A patent/CA2556320A1/en not_active Abandoned
- 2005-02-17 SI SI200530394T patent/SI1716152T1/sl unknown
- 2005-02-17 PT PT05713794T patent/PT1716152E/pt unknown
- 2005-02-17 KR KR1020067015826A patent/KR20070026380A/ko not_active Application Discontinuation
- 2005-02-17 RU RU2006129324/04A patent/RU2006129324A/ru not_active Application Discontinuation
- 2005-02-17 BR BRPI0507495-9A patent/BRPI0507495A/pt not_active IP Right Cessation
- 2005-02-17 MY MYPI20050602 patent/MY152888A/en unknown
- 2005-02-17 WO PCT/US2005/005218 patent/WO2005080397A2/en active Application Filing
-
2006
- 2006-08-03 IL IL177291A patent/IL177291A0/en unknown
-
2007
- 2007-04-30 HK HK07104630A patent/HK1098460A1/xx not_active IP Right Cessation
-
2008
- 2008-09-26 HR HR20080480T patent/HRP20080480T3/xx unknown
Also Published As
Publication number | Publication date |
---|---|
US20070185095A1 (en) | 2007-08-09 |
WO2005080397A8 (en) | 2006-06-22 |
SI1716152T1 (sl) | 2008-12-31 |
DE602005008558D1 (de) | 2008-09-11 |
ATE402935T1 (de) | 2008-08-15 |
WO2005080397A2 (en) | 2005-09-01 |
JP2007523183A (ja) | 2007-08-16 |
EP1716152A2 (en) | 2006-11-02 |
HRP20080480T3 (en) | 2008-11-30 |
MY152888A (en) | 2014-11-28 |
PT1716152E (pt) | 2008-10-02 |
EP1716152B1 (en) | 2008-07-30 |
BRPI0507495A (pt) | 2007-07-10 |
RU2006129324A (ru) | 2008-04-10 |
KR20070026380A (ko) | 2007-03-08 |
CA2556320A1 (en) | 2005-09-01 |
ES2309718T3 (es) | 2008-12-16 |
WO2005080397A3 (en) | 2005-12-22 |
PL1716152T3 (pl) | 2009-01-30 |
DK1716152T3 (da) | 2008-11-03 |
IL177291A0 (en) | 2006-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1098460A1 (en) | Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders | |
EA200601266A1 (ru) | Соединения триазола и их применение в качестве антагонистов метаботропного рецептора глутамата | |
WO2003028641A3 (en) | Mch receptor antagonists | |
TW200720260A (en) | Prokineticin 1 receptor antagonists | |
TW200716566A (en) | Prokineticin 2 receptor antagonists | |
UA84318C2 (ru) | Гетерополициклические соединения и их применение как метаботропических антагонистов рецепторов глутамата, фармацевтическая композиция на их основе | |
HK1091200A1 (en) | Arylindenopyridines and arylindenopyrimidines and their use as adenosine a2a receptor antagonists | |
MX2008001606A (es) | Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico. | |
ATE423769T1 (de) | Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten | |
TW200510429A (en) | Heterocyclic MCHR1 antagonists | |
EA200900658A1 (ru) | Производные индазолилэфиров или -амидов для лечения расстройств, опосредованных глюкокортиодными рецепторами | |
EA200501595A1 (ru) | Азабициклические производные в качестве антагонистов мускаринового рецептора | |
MX2008002805A (es) | Derivados de carboxamida como antagonistas del receptor muscarinico. | |
WO2007073303A3 (en) | Novel benzimidazole derivatives as vanilloid receptor 1 (vrl) inhibitors | |
MX2009005507A (es) | Derivados de espiro-piperidina. | |
EA200501593A1 (ru) | Азабициклические производные в качестве антагонистов мускаринового рецептора | |
MX2009006454A (es) | Derivados de espiro-piperidina. | |
MX2009005541A (es) | Indoles que actuan como antagonistas del receptor v1a. | |
NO20063562L (no) | Fusjonerte heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
MX2008001607A (es) | Piperazinas biciclicas como antagonistas del receptor de glutamato metabotropico. | |
EA200501594A1 (ru) | Замещенные производные азабициклогексана в качестве антагонистов мускаринового рецептора | |
MX2009005504A (es) | Derivados de espiro piperidina como antagonistas del receptor via. | |
UA89846C2 (ru) | Производные карбоксамида как антагонисты мускариновых рецепторов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20120217 |